Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2002-04-04
2010-02-16
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S202100, C424S218100
Reexamination Certificate
active
07662394
ABSTRACT:
The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of oneflavivirusand an immunogenicflavivirusantigen of a secondflavivirusor of a chimeric immunogenicflavivirusantigen comprising sequence from more than oneflavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject againstflavivirusinfection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detectingflavivirusor diagnosingflavivirusinfection.
REFERENCES:
patent: 4810492 (1989-03-01), Fujita et al.
patent: 5021347 (1991-06-01), Yasui et al.
patent: 5229293 (1993-07-01), Matsuura et al.
patent: 5494671 (1996-02-01), Lai et al.
patent: 5514375 (1996-05-01), Paoletti et al.
patent: 6074865 (2000-06-01), Kelly et al.
patent: 6136561 (2000-10-01), Ivy et al.
patent: 6165477 (2000-12-01), Ivy et al.
patent: 6258788 (2001-07-01), Schmaljohn
patent: 6455509 (2002-09-01), Kochel et al.
patent: 6696281 (2004-02-01), Chambers et al.
patent: 53133627 (1978-11-01), None
patent: 63105682 (1988-05-01), None
patent: 89025725 (1989-05-01), None
patent: 5276941 (1993-10-01), None
patent: 7265093 (1995-10-01), None
patent: WO 90/01946 (1990-03-01), None
patent: WO 92/02548 (1992-02-01), None
patent: WO 92/03545 (1992-03-01), None
patent: WO 93/06214 (1993-04-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 99/06068 (1999-02-01), None
patent: WO 99/63095 (1999-12-01), None
patent: WO 02/072036 (2002-09-01), None
patent: WO 02/083903 (2002-10-01), None
Pletnev, A. G., et al., 1992, “Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses”, Proc. Natl. Acad. Sci. USA 89:10532-10536.
Yasui, K, et al., 1990, “Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine”, Southeast Asian J. Trop. Med. Public Health 21(4):663-669.
Phillpotts, R. J., et al., 1996, “Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus”, Arch. Virol. 141:743-749.
Kozak, M., 1987, “At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells”, J. Mol. Biol. 196:947-950.
Rothman, A. L., 2004, Dengue: defining protective versus pathologic immunity, J. Clin. Invest. 113(7):946-951.
Stephenson, J. R., 2005, Understanding dengue pathogenesis: implications for vaccine design, Bull. World Health Org. 83:308-314 (abstract only provided).
Kitchener, S., et al., 2006, Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healty Australian adults, Vaccine 24:1238-1241.
Monath, T. P., 2007, Dengue and yellow fever-challenges for the development and use of vaccines, N. Engl. J. Med. 357(22): 2222-2225.
Stocks, C. E., and M. Lobigs, 1995, Posttranslational signal peptidase cleavage at the flavivirus C-prM junction in vitro, J. Virol. 69(12):8123-8126.
Aberle et al., “A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms,”J Immunology163:6756-6761 (1999).
Allison et al., “Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form,”J Virology69(9):5816-5820 (Sep. 1995).
Alvarez et al., “A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients,”Hum. Gene Ther. 8:229-242 (Jan. 20, 1997).
Anderson et al., “Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut,”Science286(5448):2331-2333 (Dec. 17, 1999).
Asnis et al., “The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience,”Clin. Infect. Dis. 30: 413-418 (2000).
Azevedo et al., “Main features of DNA-based immunization vectors,”Braz. J. Med. Biol. Res. 32(2):147-153 (1999).
Bray et al., “Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NSI Are Protected Against Fatal Dengue Virus Encephalitis,”J. Virol. 63(6):2853-2856 (Jun. 1989).
Cavener and Ray, “Eukaryotic start and stop translation sites,”Nucleic Acids Research, 19(12):3185-3192 (1991).
Chang et al., “A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice,”J. Virol. 74(9):4244-4252 (May 2000).
Chang et al., “Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus,”Virology, 306:170-180 (2003).
Chang et al., “Flavivirus DNA Vaccines,”Annals New York Academy of Sciences, 951:272-285 (2001).
Chang et al., “Recent advancement in flavivirus vaccine development,”Expert Rev. Vaccines, 3(2):199-220 (2004).
Chen et al., “Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice,”J Virology, 69(8):5186-5190 (Aug. 1995).
Clarke et al., “Techniques for Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses,”Amer. J. Trop. Med. And Hyg., 7:561-573 (1958).
Colombage et al., “DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against te Flavivirus, Murray Valley Encephalitis Virus,”Virology250:151-163 (1998).
Davis et al., “West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme- Linked Immunosorbent Assays,”J. Virol. 75(9):4040-4047, 2001 (published on-line Apr. 4, 2001).
Deubel et al., “Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype,” Virology 155:365-377 (1986).
Deubel et al., “Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome,”Virology165:234-244 (1988).
Dmitriev et al., “Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis,”J. Biotechnol.44:97-103 (1996).
Duarte dos Santos et al., “Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213,”Virus Res. 35:35-41 (1995).
Falgout et al., “Proper Processing of Dengue Virus Nonstructural Glycoprotein NSI Requires the N-Terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a,”J. Virol.63(5):1852-1860 (May 1989).
Falgout et al., “Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NSI Protects Against Lethal Dengue Virus Encephalitis,”J. Virol.64(9):4356-4363 (1990).
Fonseca et al., “Recombinant vaccinia viruses co-expressing dengue-1 glycoprotein prM and E induce neutralizing antibodies in mice,” Vaccine 12(3):279-285 (1994).
Garmendia et al., “Recovery and Identification of West Nile Virus from a Hawk in Winter,”J. Clin. Microbiol.38(8):3110-3111 (Aug. 2000).
Gruenberg et al., “Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains,”J. Gen. Virol., 69:1391-1398 (1988).
Guirakhoo et al., “Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates,”J. Virol., 74(12):5477-5485 (2000).
Hahn et al.,
Klarquist & Sparkman, LLP
Parkin Jeffrey S.
The United States of America as represented by the Department of
LandOfFree
Nucleic acids encoding chimeric Flavivirus immunogens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding chimeric Flavivirus immunogens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding chimeric Flavivirus immunogens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200706